Summary:

- The FDA has accepted a supplemental Biologics License Application (sBLA) for lecanemab, a treatment for early Alzheimer's disease.
- The sBLA is for a subcutaneous (under the skin) starting dose of lecanemab, which could make the treatment more convenient for patients.
- Lecanemab is currently under priority review by the FDA, which means the agency will make a decision on the treatment more quickly than usual.